Myasthenia Gravis and IVIG: What Patients Need to Know About IV Therapy

Myasthenia gravis (MG) is a chronic autoimmune disease of the neuromuscular junction in which antibodies — most commonly against acetylcholine receptors (AChR) or muscle-specific kinase (MuSK) — interfere with nerve-to-muscle signal transmission, causing fluctuating muscle weakness that worsens with activity and improves with rest.

Intravenous immunoglobulin (IVIG) plays an important role in MG management, both for acute exacerbations and as a bridge or maintenance therapy in patients with ongoing, poorly controlled disease. For stable MG patients on maintenance IVIG, home infusion therapy is an appropriate and increasingly common setting for ongoing treatment. Pharmko supports MG patients and their neurologists across 22+ states.

How IVIG Works for Myasthenia Gravis

The mechanisms by which IVIG benefits MG patients involve multiple immunomodulatory pathways:

Fc receptor blockade, IVIG saturates Fc receptors on immune cells, blocking their ability to bind and destroy acetylcholine receptors
Anti-idiotypic antibody effects, pooled IgG in IVIG preparations contains antibodies that bind and neutralize pathological anti-AChR or anti-MuSK antibodies
Complement inhibition, IVIG reduces complement-mediated damage at the neuromuscular junction
B-cell and T-cell modulation, IVIG influences the immune pathways that drive ongoing autoantibody production

The clinical effect is typically a temporary reduction in autoantibody levels and improvement in neuromuscular transmission, producing measurable improvement in strength, ptosis, diplopia, dysphagia, and respiratory function.

When IVIG Is Used in Myasthenia Gravis

Myasthenic crisis and acute exacerbations

IVIG is a first-line intervention for myasthenic crisis, a life-threatening exacerbation characterized by severe weakness of the respiratory muscles requiring intubation or intensive monitoring. Along with plasma exchange (plasmapheresis), IVIG is used to rapidly reduce autoantibody levels and restore neuromuscular function. Both are considered equivalent in efficacy for crisis management; the choice between them is guided by availability, patient tolerance, and clinical circumstances.

For acute exacerbations that fall short of crisis, worsening weakness before surgery, infection-triggered deterioration, or inadequate control on maintenance immunosuppression, IVIG provides a rapid, reliable bridge while longer-acting immunosuppressants are adjusted.

Pre-surgical preparation (thymectomy)

Patients with MG undergoing thymectomy or other major surgery often receive IVIG in the weeks before the procedure to optimize neuromuscular function and reduce the risk of post-operative myasthenic crisis. This is typically administered in a clinical setting given the procedural context.

Maintenance therapy

Some MG patients, particularly those who cannot tolerate corticosteroids or steroid-sparing agents, or who have breakthrough symptoms despite optimal oral immunosuppression, require ongoing maintenance IVIG to maintain adequate functional control. For these patients, regular infusions every 4 to 6 weeks provide consistent immunomodulation. Home infusion is appropriate for stable maintenance patients once their dose and schedule are established.

IVIG Dosing for Myasthenia Gravis

For acute exacerbations and crisis management, standard IVIG dosing is 2 g/kg total over 2 to 5 days, the same induction protocol used for other neurological indications. Clinical improvement typically begins within 3 to 7 days of completing the course and peaks at 2 to 3 weeks.

For maintenance therapy, dosing is individualized based on the patient's baseline disease severity, frequency of exacerbations, and response to treatment. Common maintenance schedules include 1 g/kg every 4 to 6 weeks, or 0.4–0.5 g/kg every 3 to 4 weeks. The neurologist adjusts the schedule based on the patient's functional trajectory and symptom pattern between doses.

IVIG vs Plasma Exchange for MG

Plasma exchange (plasmapheresis or PLEX) and IVIG are both effective for acute MG management, and both are used in clinical practice. Key differences:

Onset: PLEX may produce more rapid improvement (within 1–3 days) compared to IVIG (3–7 days)
Duration: IVIG effect typically lasts 4–8 weeks; PLEX effect is similar in duration
Access requirement: PLEX requires central venous access and specialized equipment; IVIG requires only a peripheral or central IV line
Side effects: PLEX carries risks related to catheter placement and fluid shifts; IVIG carries risks of headache, thrombosis, and kidney injury in high-risk patients
Availability: IVIG is more widely available and can be administered in any home infusion setting; PLEX requires specialized centers

For long-term maintenance, IVIG is more practical and widely used. PLEX is more commonly reserved for acute crises, pre-surgical optimization, and situations where IVIG is contraindicated or ineffective.

Home IVIG for Myasthenia Gravis: What to Expect

MG patients who transition to home IVIG maintenance typically have a well-established dose and schedule, have tolerated their infusions without significant reactions, and have been assessed by their neurologist as clinically stable. The home infusion experience is similar to that of other IVIG indications, a Pharmko nurse visits your home, administers pre-medications if ordered, monitors vital signs throughout the infusion, and documents the session.

Our guide on IVIG therapy at home covers the full setup process for any IVIG indication. For broader context on immune-mediated neurological conditions treated with IVIG, including CIDP and primary immune deficiency, those guides provide parallel reference points that MG patients and their families often find useful.

Insurance Coverage for IVIG in Myasthenia Gravis

IVIG is covered by Medicare Part B and most commercial insurance plans for MG when documentation supports medical necessity, confirmed diagnosis with antibody testing, severity of clinical presentation, and evidence of inadequate control or intolerance to standard immunosuppressive therapy. Pharmko manages prior authorization and works with your neurologist's office to compile the required clinical documentation and submit the authorization request.

→ Contact Pharmko to start MG IVIG therapy: 1-877-540-2003 · info@pharmko.com

< Older Post

Dobutamine and Inotrope Therapy at Home: Advanced Heart Failure Care

July 17, 2026

Learn how home dobutamine infusion works for advanced heart failure, who qualifies, how continuous inotrope therapy is managed at home, and how Pharmko supports cardiac patients and heart failure teams.

CIDP and Home Infusion: IVIG Treatment, Dosing Schedule, and Long-Term Management

July 16, 2026

Learn how IVIG therapy works for CIDP, what the dosing schedule looks like, how to transition to home infusion, and how Pharmko supports long-term CIDP management across 22+ states.

Compounded IV Medications: When Are They Necessary and How Are They Made?

July 15, 2026

Most medications that patients receive at a hospital or pharmacy come in standardized, commercially manufactured forms, a 500mg antibiotic vial, a pre-filled syringe, a fixed-concentration IV bag. These products work well for many patients. But a significant portion of patients receiving IV therapy have clinical needs that commercial products cannot meet: a dose the manufacturer doesn't make, a formulation incompatible with the patient's allergy profile, or a combination of nutrients that must be tailored to individual lab values. For these patients, compounded IV medications are not optional, they are clinically necessary. Pharmko's sterile compounding services prepare customized IV medications for patients across 22+ states, with every formulation reviewed by a licensed pharmacist and prepared in a USP <797> compliant cleanroom. What Makes an IV Medication 'Compounded'? A compounded medication is one that is prepared specifically for an individual patient by a licensed pharmacist, rather than manufactured in bulk by a pharmaceutical company. Compounding involves combining, mixing, or altering ingredients, active pharmaceutical ingredients, diluents, preservatives, to create a final preparation that meets the patient's unique prescription requirements. For IV therapy specifically, compounding means preparing a sterile preparation, one that is completely free of viable microorganisms and safe to inject or infuse directly into the bloodstream. This requires specialized facilities, equipment, training, and quality systems that go far beyond what a standard retail pharmacy can provide. Pharmko is exclusively a sterile compounding pharmacy. We do not compound oral medications, topical creams, or non-sterile preparations. Every product we make is intended for intravenous, intraperitoneal, or subcutaneous administration. When Are Compounded IV Medications Necessary? The required dose doesn't exist commercially Pharmaceutical manufacturers produce medications in standardized strengths and volumes based on average patient needs. Pediatric patients, patients with renal or hepatic impairment requiring dose adjustments, or patients whose weight or clinical status falls outside standard ranges may need concentrations or volumes that no commercial product provides. Compounding fills this gap precisely. The patient has an allergy to a commercial formulation's inactive ingredients Commercial IV products often contain preservatives, stabilizers, or diluents, sulfites, benzyl alcohol, certain dyes, that some patients cannot tolerate. A compounding pharmacy can prepare an equivalent formulation without the offending ingredient, allowing the patient to receive the therapy safely. The medication requires individualized nutrient formulation Total parenteral nutrition (TPN) is the clearest example: every TPN formula must be individually compounded because no commercial product can provide the precise combination of amino acids, dextrose, lipids, electrolytes, vitamins, and trace minerals a specific patient needs. The formula changes as the patient's labs, weight, and clinical status change, making standardization impossible. The commercial product is unavailable or in shortage Drug shortages are a persistent reality in the US pharmaceutical supply chain. When a commercially manufactured IV medication becomes unavailable, compounding pharmacies can often prepare an equivalent formulation from available active pharmaceutical ingredients, bridging the gap and maintaining continuity of therapy for patients who cannot wait. The therapy requires a custom delivery format Some IV medications require specific pH, osmolarity, or concentration adjustments for compatibility with a patient's IV access device or concurrent medications. A compounding pharmacist reviews compatibility and prepares formulations that are safe and stable for the specific administration route and equipment the patient is using. How Compounded IV Medications Are Made Step 1: Prescription review Every compounded IV medication begins with a valid prescription from a licensed prescriber. Pharmko's pharmacists review the prescription for clinical appropriateness, dosing accuracy, ingredient compatibility, and stability before compounding begins. Step 2: Ingredient sourcing and verification Active pharmaceutical ingredients for compounding must come from FDA-registered suppliers and meet USP monograph specifications. Each lot is verified for identity, potency, and purity before use. Step 3: Sterile preparation in a controlled environment Preparation occurs in an ISO Class 5 laminar airflow workbench or biological safety cabinet, located within a buffer room that meets ISO Class 7 air quality standards. Pharmacy technicians follow validated, written procedures for each preparation type, using aseptic technique to prevent contamination at every step. Step 4: Pharmacist verification and release A licensed pharmacist performs a final check of every preparation, verifying appearance, volume, labeling, and documentation, before the product is released. High-risk or complex preparations may undergo sterility testing with defined beyond-use dates based on test results. Step 5: Cold-chain delivery Most compounded IV medications require refrigeration. Pharmko uses validated cold-chain packaging and delivery logistics to ensure products arrive within their stability windows and remain temperature-controlled until the patient uses them. Quality Standards That Matter Not all compounding pharmacies operate at the same standard. The relevant quality benchmarks for sterile compounding are: USP <797> compliance, the national standard for sterile compounding environments, personnel, and processes. Our guide on USP <797> and USP <800> explains what compliance means in practice ACHC accreditation, independent third-party verification that Pharmko meets clinical quality standards for home infusion and sterile compounding State pharmacy board licensure, Pharmko is licensed in every state where we serve patients Environmental and personnel monitoring, documented air and surface sampling, personnel gowning competency assessments, and media fill testing at defined intervals For a foundational overview of what sterile compounding is and how it differs from retail pharmacy, see our guide on what is sterile compounding for IV therapy . → Contact Pharmko about compounded IV medications: 1-877-540-2003